Through a Series B financing, CREATE Medicines will support clinical advancement of its in vivo CAR-T candidates for autoimmune disease and oncology indications.
CREATE Medicines, a US-based clinical-stage biotechnology company, has raised $122 million in
The financing round was co-led by existing investors ARCH Venture Partners, Newpath Partners, and Hatteras Venture Partners, with participation from Alexandria Venture Investments and other current investors. According to the company, the funding will support advancement of its autoimmune disease and oncology pipeline, including progression of its lead autoimmune candidate, CRT-402, toward clinical development.
More than 50 patients have been dosed across the company’s in vivo CAR clinical programs, which houses the largest clinical dataset currently available in the field of
“CREATE was built as an iterative immune programming platform in which each clinical study informs and strengthens the next, and it is that work that has revealed the breadth of what in vivo immune programming can address,” said
CREATE’s lead autoimmune program, CRT-402, is a CD19-targeted in vivo CAR-T therapy designed to support repeat dosing strategies in autoimmune disease. According to the company, the candidate demonstrated deep and durable B-cell depletion in non-human primate studies.1
The company is also advancing a dual CAR therapy targeting CD19 and B-cell maturation antigen, intended to broaden therapeutic activity across refractory autoimmune diseases. CREATE’s in vivo approach is designed to directly engineer immune cells within the patient, potentially reducing manufacturing complexity associated with ex vivo cell therapies while enabling scalable treatment approaches.
In oncology, the company continues development of multiple immunotherapy programs targeting areas of unmet medical need. It highlighted early clinical findings from its MT-303 program in frontline hepatocellular carcinoma.2 The MT-303 program has demonstrated an “extremely compelling response profile” in early clinical evaluation, although detailed efficacy data were not disclosed.1
The company’s broader platform integrates clinically validated CAR constructs, optimized RNA design, and targeted delivery technologies. The company also emphasized internal capabilities spanning translational medicine, manufacturing, regulatory strategy, and clinical development.
“We believe our ability to engineer multiple immune cell populations directly in vivo has the potential to fundamentally reshape treatment paradigms across autoimmune disease and oncology,” Getts said in the release.1
The Series B financing coincides with several leadership additions to the company, including the appointment of
“I’m excited to join CREATE at this pivotal moment in the company’s evolution,” Philip said in the release.1 “CREATE has established meaningful in vivo clinical proof points and built a differentiated immune programming platform with the potential to redefine how engineered immune therapies are developed and delivered.”
The company’s proprietary platform supports engineering of T cells, natural killer cells, and myeloid cells directly in vivo. The company’s development strategy focuses on repeat-dose immune programming approaches intended to expand treatment applications across autoimmune diseases and cancer.
